Active, not recruiting

2b

147

US

N-803 + Pembrolizumab, N-803 + Nivolumab, N-803 + Atezolizumab, N-803 + Avelumab, N-803 + Durvalumab, N-803 + Pembrolizumab + PD-L1 t-haNK, N-803 + Nivolumab + PD-L1 t-haNK, N-803 + Atezolizumab + PD-L1 t-haNK, N-803 + Avelumab + PD-L1 t-haNK, N-803 + Durvalumab + PD-L1 t-haNK

ImmunityBio, Inc.

Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma, Merkel Cell Carcinoma, Melanoma, Renal Cell Carcinoma, Gastric Cancer, Cervical Cancer, Hepatocellular Carcinoma, Microsatellite Instability, Mismatch Repair Deficiency, Colorectal Cancer

05/24

12/24

Active, not recruiting

2

28

Japan

Tecentriq (atezolizumab) - Roche, Avastin (bevacizumab) - Roche

Kanazawa University Hospital

Hepatocellular carcinoma

 

 

Recruiting

2

33

Japan

cisplatin - Generic mfg., vinorelbine tartrate - Generic mfg., Tecentriq (atezolizumab) - Roche

Kitakyushu Municipal Medical Center, Chugai Pharmaceutical Co., Ltd.

Non-small cell lung cancer

 

 

Completed

2

310

Europe, Canada, US

Atezolizumab, MPDL3280A, Tecentriq

Hoffmann-La Roche

Bladder Cancer

07/16

02/23

Ongoing

2

43

Europe

TECENTRIQ, [R00554-1267/F03-01], Concentrate for solution for infusion, TECENTRIQ - 1200 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) - 20 ML (60 MG/ML) - 1 FLACONCINO

GRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC), Roche Spa

Advanced Non-small cell lung cancer (NSCLC) with rare histological subtypes Carcinoma polmonare non a piccole cellule avanzato (NSCLC) pretratto, con sottotipi istologici rari, Advanced Non-small cell lung cancer with rare histologies Carcinoma polmonare non a piccole cellule con sottotipi istologici rari, Diseases [C] - Cancer [C04]

 

 

Active, not recruiting

2

135

Europe, US, RoW

Atezolizumab, Tecentriq, Tiragolumab, MTIG7192A, Placebo

Genentech, Inc.

Non-small Cell Lung Cancer

06/19

03/25

Not yet recruiting

2

103

Europe

atezolizumab, RO5541267, Concentrate for solution for infusion, Tecentriq

Centre Antoine Lacassagne, Institut National du Cancer, Roche SAS

Soft tissue sarcoma Sarcomes des tissus mous, Soft tissue sarcoma Sarcomes des tissus mous, Diseases [C] - Cancer [C04]

 

 

Active, not recruiting

2

65

US

Bevacizumab, Avastin, Atezolizumab, RG-7446

Dana-Farber Cancer Institute, Genentech, Inc.

Advanced Non-Clear Cell Kidney Cancer

11/19

10/24

Not yet recruiting

2

154

Europe

Tecentriq, Cotellic, Zejula, Everolimus, RO5514041/F04, Concentrate for solution for infusion, Film-coated tablet, Capsule, hard, Tablet, Tecentriq, Cotellic, Zejula

Uppsala University Hospital, Roche AB

In part 1 of the study: any solid tumor with the exemption of sarcoma. In part 2: any solid tumor or hematological malignancy, In part 1 of the study: any solid tumor with the exemption of sarcoma. In part 2: any solid tumor or hematological malignancy, Diseases [C] - Cancer [C04]

 

 

Ongoing

2

104

Europe

Atezolizumab, [RO554-1267], Concentrate for solution for infusion

CONSORZIO ONCOTECH, Roche spa

Metastatic Triple-negative PD-L1 positive breast cancer Carcinoma mammario metastatico Triplo-negativo PD-L1 positivo, metastatic Triple-negative PD-L1 positive breast cancer carcinoma mammario metastatico PD-L1 positivo e particolarmente difficile da trattare, Diseases [C] - Cancer [C04]

 

 

Not yet recruiting

2

300

Europe

Zejula, Capsule, hard, Concentrate and solvent for solution for infusion, Tablet, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Alcensa, Tecentriq, Cotellic, Zelboraf, Herceptin, Perjeta, Kadcyla, Erivedge, Bavencio, Inlyta, Zejula, pemazyre, Retsevmo

Rigshospitalet, Roche, Pfizer

Eligible patients will have an advanced malignant disease for which standard treatment options are no longer available or feasible and acceptable performance status and organ function. Patienter med fremskreden og/eller metastatisk solid tumor, som har oplevet progression under standardbehandling, eller som er intolerante over for standardbehandling, Patients with advanced cancer without curative therapeutic options Patienter med fremskreden kræft uden mulighed for kurativ behandling, Diseases [C] - Cancer [C04]

 

 

Not yet recruiting

2

104

Europe

Concentrate for solution for infusion, Tecentriq® 1.200 mg

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Roche Pharma AG, Roche

Small cell lung cancer extensive disease, Small cell lung cancer extensive disease, Diseases [C] - Cancer [C04]

 

 

Not yet recruiting

2

52

Europe

atezolizumab, RO5541267, Solution for infusion, Concentrate for solution for infusion, CAPÉCITABINE MYLAN, OXALIPLATINE HOSPIRA, Avastin, Tecentriq

Fédération Francophone de Cancérologie Digestive, ROCHE, Boston Scientific

MICROSATELLITE STABLE (MSS) COLORECTAL CANCER WITH LIVER-DOMINANT METASTASIS, METASTATIC COLORECTAL CANCER WITH SPECIFIC MOLECULAR PROFIL (MSS) AND LIVER-DOMINANT METASTASIS, Diseases [C] - Cancer [C04]

 

 

Ongoing

2

20

Europe

Concentrate and solvent for solution for infusion, Powder and solvent for solution for infusion, Tecentriq, Abraxane, CARBOplatin Kabi

Ruprecht-Karls University Heidelberg, Medical Faculty, repr. by HD University Hospital and its Commercial Managing Dir., Roche Pharma AG

resectable Stage II, IIIA and select IIIB non-squamous Non-Small Cell Lung Cancer, Diseases [C] - Cancer [C04]

 

 

Not yet recruiting

2

150

Europe

Atezolizumab, Bevacizumab, RO5541267/F03, RO4876646/F02, Concentrate for solution for infusion, Tecentriq, Avastin

F. Hoffman-La Roche Ltd., F. HOFFMANN - LA ROCHE LTD., F. Hoffmann-La Roche Ltd., F.Hoffmann-La Roche Ltd.

Biliary tract cancer, Biliary tract cancer is a rare type of cancer that occurs in a bile duct. Patients with advanced biliary tract cancer generally have a poor prognosis., Diseases [C] - Cancer [C04]

 

 

Terminated

2

26

Europe

Atezolizumab, Tecentriq

European Organisation for Research and Treatment of Cancer - EORTC, Hoffmann-La Roche

Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides/Sezary Syndrome

03/21

08/22

Not yet recruiting

2

40

Europe

Atezolizumab, tocilizumab, Concentrate for solution for infusion, Tecentriq, Actemra

University Hospital Essen, Hoffmann-La Roche Ltd

local squamous cell carcinoma of the head and neck, local squamous cell carcinoma of the head and neck, Diseases [C] - Cancer [C04]

 

 

Not yet recruiting

2

67

Europe

Concentrate for solution for infusion, Tecentriq®

Technische Universität Dresden, ROCHE Pharma AG

locally advanced or metastatic large-cell neuroendocrine carcinoma of the lung (LCNEC) not eligible for curative treatment lokal fortgeschrittenes oder metastasiertes großzellig-neuroendokrines Lungenkarzinom (LCNEC), nicht für eine kurative Behandlung geeignet, locally advanced or metastatic large-cell neuroendocrine carcinoma of the lung not eligible for curative treatment, Diseases [C] - Cancer [C04]

 

 

Completed

2

21

US

Ramucirumab, Cyramza, Atezolizumab, Tecentriq, Peripheral blood draw, Biopsy

Washington University School of Medicine, Eli Lilly and Company

Non-small Cell Lung Cancer, Non Small Cell Lung Cancer, NSCLC

07/21

04/24

Not yet recruiting

2

190

Europe

Herceptin, Tecentriq, Kadcyla, Docetaxel, Carboplatin, Epirubicin, Cyclophosphamide, Pertuzumab, Paklitaxel, Solution for injection, Solution for infusion, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Powder for solution for injection/infusion, Herceptin, Tecentriq, Kadcyla

Karolinska University Hospital, Karolinska University Hospital

Primary breast cancer, Newly diagnosed HER2 amplified breast cancer, Diseases [C] - Cancer [C04]

 

 

Not yet recruiting

2

80

Europe

Atezolizumab, IMM-101, L01XC32, Concentrate for solution for infusion, Suspension for injection, Tecentriq (R)

AIO-Studien-gGmbH, F. Hoffmann-La Roche Ltd, Immodulon Therapeutics Ltd.

Patients with MSI-high or MMR-deficient stage III colorectal cancer who are ineligible for or who refuse oxaliplatin-based chemotherapy after R0 tumor resection (main study) or planned resection (sub-study), patients with stage III colon or rectum cancer who are ineligible or refuse oxaliplatin-based chemotherape after surgical removal of the tumor (main study) oder the surgery is planned (sub-study), Diseases [C] - Cancer [C04]

 

 

Not yet recruiting

2

37

Europe

Derazantinib, Derazantinib•2HCl / BAL087 / BAL0000087-001, Concentrate for solution for infusion, Capsule, hard, Tecentriq® 1.200 mg

Frankfurter Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, ROCHE Pharma AG, Basilea Pharmaceutica International Ltd.

Advanced non-resectable intrahepatic cholangiocarcinoma with positively confirmed FGFR2 fusion/rearrangements via NGS-Analysis, Advanced and inoperable intrahepatic bile duct cancer with positively confirmed FGFR2 genetic alterations, Diseases [C] - Cancer [C04]

 

 

Completed

2

20

RoW

Atezolizumab, Tecentriq, Bevacizumab, Avastin, Oxaliplatin, Levoleucovorin, 5-FU, 5-fluorouracil

Asan Medical Center, Hoffmann-La Roche

Colorectal Neoplasms, Neoplasm Metastasis, Colonic Neoplasms, Rectal Neoplasms

12/21

10/23

Recruiting

2

20

Europe

Atezolizumab, MPDL3280A, Capecitabine, L01BC06, Oxaliplatin, L01XA03, Docetaxel, L01CD02

The Netherlands Cancer Institute, Hoffmann-La Roche

Stomach Cancer, Gastro Esophageal Junction Cancer

01/22

01/22

Terminated

2

6

US

Carboplatin, paraplatin, Gemcitabine, Gemzar, Atezolizumab, Tecentriq, Docetaxel, Taxotere

Nabil Adra, Genentech, Inc., Indiana University School of Medicine

Urothelial Carcinoma

03/22

05/22

Terminated

2

1

US

Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Radiation Therapy, Cancer Radiotherapy, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Therapeutic Conventional Surgery

Arnaud Bewley, MD, National Cancer Institute (NCI), Genentech, Inc.

Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8

05/22

04/23

Active, not recruiting

2

56

RoW

Atezolizumab, Tecentriq, Cisplatin, Carboplatin, Etoposide, Thoracic radiation therapy (TRT)

Hoffmann-La Roche

Carcinoma, Small Cell Lung

06/22

06/24

Active, not recruiting

2

11

US

Vorolanib, X-82, Atezolizumab, Tecentriq

Washington University School of Medicine, Xcovery Holdings, Inc.

Extensive-stage Small Cell Lung Cancer

08/22

07/25

Recruiting

2

24

RoW

LW-02 device immunopheresis combined with atezolizumab, Plasma soluble TNF receptor pulldown + immunotherapy., LW-02 device immunopheresis combined with weekly paclitaxel, Plasma soluble TNF receptor pulldown + chemotherapy, LW-02 device immunopheresis, Plasma soluble TNF receptor pulldown

Immunicom Inc

Non Small Cell Lung Cancer

08/22

12/22

Terminated

2

3

US

Carboplatin, paraplatin, Etoposide, VP-16, Atezolizumab, Imfinzi

Jeffrey Clarke, Genentech, Inc., Duke University

Small-cell Lung Cancer, Brain Metastases

07/22

09/22

Ongoing

2

45

Europe

Tiragolumab, Atezolizumab, Concentrate for solution for infusion, TECENTRIQ

Grupo Español Multidisciplinar de Cáncer Digestivo (GEMCAD), ROCHE Ltd

Locallized squamous cell carcinoma of the anal canal in the first-line setting. Carcinoma epidermoide localizado del canal anal en primera línea., Carcinoma of the anal canal Carcinoma del canal anal, Diseases [C] - Cancer [C04]

 

 

Terminated

2

1

US

Talazoparib, Talzenna, Atezolizumab, Tecentriq, Radiation

Mylin A. Torres, MD, Genentech, Inc., Pfizer, Emory University

Breast Cancer, Triple Negative Breast Cancer

02/22

12/22

2

71

Europe

Atezolizumab, Cobimetinib, Ipatasertib, Bevacizumab

Queen Mary University of London, Kliniken Essen-Mitte, MedSIR, Asan Medical Center, Hoffmann-La Roche

Breast Cancer, Estrogen Receptor-positive Breast Cancer

Active, not recruiting

2

99

Europe

MPDL3280A, atezolizumab, mDCF, modified docetaxel, cisplatin, and fluorouracil

GERCOR - Multidisciplinary Oncology Cooperative Group, Roche Pharma AG

Anal Cancer

02/23

12/24

Completed

2

25

US

TJ004309

I-Mab Biopharma US Limited

Ovarian Cancer, Head and Neck Cancer, Non Small Cell Lung Cancer, Gastrointestinal Cancer, Triple Negative Breast Cancer, Ovarian Carcinoma

02/23

02/23

Not yet recruiting

2

40

Europe

Atezolizumab, tiragolumab, RO5541267, RO7092284/F03-01, Concentrate for solution for infusion, Tecentriq

Roche Farma S.A.U., Roche Farma S.A.U.

Solid tumors Tumores sólidos, Solid tumors are abnormal mass of tissue that usually does not contain cysts or liquid areas. Solid tumors may be benign (not cancerous), or malignant (cancerous) Los tumores sólidos son masas anormales de tejido que generalmente no contienen quistes o áreas líquidas. Los tumores sólidos pueden ser benignos (no cancerosos) o malignos (cancerosos), Diseases [C] - Cancer [C04]

 

 

Completed

2

23

US

Atezolizumab, MPDL3280A

Lawrence Fong, Genentech, Inc., The Bladder Cancer Advocacy Network, Conquer Cancer Foundation, National Cancer Institute (NCI), The V Foundation

Carcinoma, Transitional Cell

03/23

03/23

Not yet recruiting

2

75

Europe

Atezolizumab, Caelyx, Sendoxan, MPDL3280A-RO5541267-F-03, Solution for infusion, Concentrate and solvent for concentrate for solution for infusion, Tablet, Tecentriq, Caelyx, Sendoxan

Oslo University Hospital (OUS), Roche

Triple-negative breast cancer patients With matasteses, Metastatic triple-negative breast cancer, Diseases [C] - Cancer [C04]

 

 

Completed

2

673

US

Trastuzumab, Herceptin, Pertuzumab, Perjeta, Erlotinib, Tarceva, Vemurafenib, Zelboraf, Cobimetinib, Cotellic, Vismodegib, Erivedge, Alectinib, Alecensa, Atezolizumab, Tecentriq

Genentech, Inc.

Neoplasms, Solid Tumors, Biliary Cancer, Salivary Cancer, Bladder Cancer

05/23

05/23

Recruiting

2

58

Europe

Atezolizumab, MPDL3280A

Queen Mary University of London, Hoffmann-La Roche

Urogenital Cancer

07/23

12/24

Active, not recruiting

2

416

Europe

Atezolizumab 840 MG in 14 ML Injection, Tecentriq, Atezolizumab 1200 MG in 20 ML Injection, Carboplatin, Paclitaxel, Epirubicin, Cyclophosphamide, Biopsy Arm A, Biopsy Arm B, Surgery

Palleos Healthcare GmbH, Roche Pharma AG, Phaon Scientific GmbH, University Hospital, Essen, University Hospital Erlangen

Triple-negative Breast Cancer

07/23

08/24

Recruiting

2

69

Europe

Pre-operative radiotherapy followed by 2 cycles of atezolizumab then surgery, 2 cycles of atezolizumab followed by surgery then post-operative radiotherapy, Pre-operative radiotherapy followed by surgery then 2 cycles of atezolizumab.

Centre Leon Berard, Roche Pharma AG

Sarcoma,Soft Tissue

08/23

08/24

Recruiting

2

38

Europe

Atezolizumab, MPDL3280A, Bevacizumab, HCA 185 ,Avastin

The Netherlands Cancer Institute, Hoffmann-La Roche

Rectal Cancer

08/23

08/24

Active, not recruiting

2

91

US

IPI-549 (eganelisib), Atezolizumab, Tecentriq, nab-paclitaxel, Abraxane, Bevacizumab, Avastin

Infinity Pharmaceuticals, Inc., Roche Pharma AG

Breast Cancer, Renal Cell Carcinoma

08/23

08/23

Recruiting

2

20

US

Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Transoral Surgery with cervical lymphadenctomy (neck dissection), Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging

Emory University, National Cancer Institute (NCI), Genentech, Inc.

Oropharynx Cancer, Stage I

08/25

08/26

Active, not recruiting

2

186

Europe

Rucaparib, CO-338, Abemaciclib, LY2835219, pembrolizumab & bemcentinib, Keytruda; BGB324, Atezolizumab & Bevacizumab, MPDL3280A; Avastin, Dostarlimab and Niraparib, Zejula

University of Leicester, British Lung Foundation, Clovis Oncology, Inc., Eli Lilly and Company, Merck Sharp & Dohme LLC, BerGenBio ASA, Roche Pharma AG, University Hospitals, Leicester, The Christie NHS Foundation Trust, GlaxoSmithKline

Mesothelioma, Malignant

10/23

10/23

Recruiting

2

50

RoW

Lenvatinib

Asan Medical Center, Eisai Inc., Chonnam National University Hospital, Seoul National University, Gangneung Asan Hospital, Ulsan University Hospital, Chosun University Hospital, Dong-A University Hospital, Bundang CHA Hospital, Seoul National University Bundang Hospital, Yonsei University, Hanyang University Seoul Hospital, Chungnam National University Hospital, Saint Vincent's Hospital, Korea, Gyeongsang National University Hospital, Ewha Womans University, Chungbuk National University Hospital, Severance Hospital, Gachon University Gil Medical Center, The Catholic University of Korea, Bucheon St. Mary's Hospital

Hepatocellular Carcinoma

11/26

11/27

Not yet recruiting

2

50

Europe, RoW

VB10.16, Atezolizumab, VB10.16, Atezolizumab, Solution for injection, Concentrate for solution for infusion, Tecentriq

Nykode Therapeutics ASA, NYKODE THERAPEUTICS ASA, Nykode Therapeutics A.S., VACCIBODY A.S., Nykode Therapetics ASA, NYKODE THERAPEUTICS ASA, Nykode Therapeutics ASA, Nykode Therapeutics A.S., VACCIBODY AS

Advanced or recurrent non-resectable HPV16-positive cervical cancer, who failed or are not eligible for current standard of care, Advanced cervical cancer, Diseases [C] - Cancer [C04]

 

 

Active, not recruiting

2

212

Europe

Atezolizumab, anti-PDL1, Tecentriq

Norwegian University of Science and Technology, University Hospital of North Norway, Alesund Hospital, Vestre Viken Hospital Trust, University Hospital, Akershus, Helse Nord-Trøndelag HF, Helse Stavanger HF, Haukeland University Hospital, Sorlandet Hospital HF, Ullevaal University Hospital, Molde Hospital, Helse Fonna, Nordlandssykehuset HF, Volda Hospital, Kristiansund Hospital, Sahlgrenska University Hospital, Sweden, Skane University Hospital, Karolinska University Hospital, Ôrebro University Hospital, Gävle Hospital, University Hospital, Linkoeping, Odense University Hospital, Aalborg University Hospital, Rigshospitalet, Denmark, National Cancer Institute, Lithuania, Kantonsspital Winterthur KSW, University Hospital, Basel, Switzerland, Insel Gruppe AG, University Hospital Bern, Kantonsspital Graubünden, Freiburger Spital, Klinik Hirslanden, Zurich, Kantonsspital Olten, Spital STS AG, Ente Ospedaliero Cantonale, Bellinzona, Cantonal Hospital of St. Gallen, St. Olavs Hospital, Oslo University Hospital, Rijnstate Hospital, Isala, Zuyderland Medisch Centrum, The Netherlands Cancer Institute, St. Antonius Hospital, Amphia Hospital, Medisch Spectrum Twente, Erasmus Medical Center

Small-cell Lung Cancer

04/24

04/27

Active, not recruiting

2

70

Europe

Atezolizumab

AIO-Studien-gGmbH, Hoffmann-La Roche

SCLC, Extensive Stage

04/24

10/24